We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $60.55, moving -0.03% from the previous trading session. This move lagged the S&P 500's daily gain of 0.47%. Elsewhere, the Dow gained 0.4%, while the tech-heavy Nasdaq added 0.33%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 5.67% in the past month. In that same time, the Medical sector lost 1.81%, while the S&P 500 gained 3.42%.
Wall Street will be looking for positivity from GILD as it approaches its next earnings report date. This is expected to be October 28, 2020. In that report, analysts expect GILD to post earnings of $1.87 per share. This would mark year-over-year growth of 6.86%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.30 billion, up 12.43% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.84 per share and revenue of $24.11 billion, which would represent changes of +3.17% and +7.39%, respectively, from the prior year.
Any recent changes to analyst estimates for GILD should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.05% lower. GILD is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that GILD has a Forward P/E ratio of 8.85 right now. Its industry sports an average Forward P/E of 25.1, so we one might conclude that GILD is trading at a discount comparatively.
We can also see that GILD currently has a PEG ratio of 0.68. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.55 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 177, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $60.55, moving -0.03% from the previous trading session. This move lagged the S&P 500's daily gain of 0.47%. Elsewhere, the Dow gained 0.4%, while the tech-heavy Nasdaq added 0.33%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 5.67% in the past month. In that same time, the Medical sector lost 1.81%, while the S&P 500 gained 3.42%.
Wall Street will be looking for positivity from GILD as it approaches its next earnings report date. This is expected to be October 28, 2020. In that report, analysts expect GILD to post earnings of $1.87 per share. This would mark year-over-year growth of 6.86%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.30 billion, up 12.43% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.84 per share and revenue of $24.11 billion, which would represent changes of +3.17% and +7.39%, respectively, from the prior year.
Any recent changes to analyst estimates for GILD should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.05% lower. GILD is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that GILD has a Forward P/E ratio of 8.85 right now. Its industry sports an average Forward P/E of 25.1, so we one might conclude that GILD is trading at a discount comparatively.
We can also see that GILD currently has a PEG ratio of 0.68. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.55 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 177, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.